PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...

Sanofi's Genzyme rare diseases division already sells another enzyme replacement therapy for Pompe disease based on the recombinant enzyme alglucosidase alfa – sold as Myozyme in Europe and ...